Bio-Europe

The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.

Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.

Medixci’s Nick Williams told attendees at BIO-Europe that it was a shame that promising biotechs head to the NASDAQ as soon as possible. He and called for a change in culture from investors and for them to back the continent’s start-ups with proper funding.

Selwyn Ho, CEO of Medigene, discusses the company’s pipeline strategy and upcoming milestones for its immuno-oncology platform.